Phase II Pilot Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Early Stage Primary Sclerosing Cholangitis
|ClinicalTrials.gov Identifier: NCT00004762|
Recruitment Status : Completed
First Posted : February 25, 2000
Last Update Posted : June 24, 2005
I. Evaluate the effects of cladribine (2-chlorodeoxyadenosine; 2-CdA) on biochemical, radiologic, and histologic parameters in patients with early stage primary sclerosing cholangitis.
|Condition or disease||Intervention/treatment||Phase|
|Cholangitis, Sclerosing||Drug: cladribine||Phase 2|
Patients are treated with subcutaneous injections of cladribine (2-chlorodeoxyadenosine; 2-CdA) for 5 consecutive days every month for 3 months.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||5 participants|
|Study Start Date :||December 1994|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004762
|Study Chair:||Paul J. Pockros||Scripps Clinic|